期刊文献+

腮腺炎减毒活疫苗国家参考品的制备及标定 被引量:3

Preparation and calibration of the national reference for titration of live attenuated mumps vaccine virus
原文传递
导出
摘要 目的:制备腮腺炎减毒活疫苗国家参考品,并进行标定。方法:选用国内腮腺炎疫苗生产毒株S79制备腮腺炎疫苗参考品。在生产过程中严格控制精密性、水分含量,对候选参考品进行鉴别试验、病毒滴度、水分含量、牛血清蛋白残留量及无菌检查等试验。检验合格后组织4个实验室对候选参考品病毒滴度进行协作标定,计算实验室内变异及实验室间变异系数;对候选国家参考品进行稳定分析。结果:制备的候选参考品鉴别试验、无菌检查结果均符合规定,水分含量为1.6%。经协作标定,腮腺炎减毒活疫苗病毒滴定候选国家参考品的病毒滴度为(4.96±0.38)lgCCID50·mL^-1,实验室内变异系数在2.0%-4.1%之间;稳定性考核数据显示制备的参考品具有较好的稳定性。结论:制备的参考品符合作为腮腺炎减毒活疫苗国家参考品的要求。 Objective: To prepare and calibrate the national reference for titration of live attenuated mumps vaccine virus. Methods: Live attenuated mumps vaccine reference was prepared with S79 strain which was used for vaccine production in China,and subjected to control tests such as identity test,determination of moisture,virus titration and sterility test. The candidate references were calibrated in collaboration by four laboratories,based on which the intra-and inter-coefficients of variation( CVs) were calculated,and the stability of candidate reference was analyzed. Results: The prepared candidate reference was qualified in identity and sterility tests,of which the moisture content was 1. 6%. The result of collaborative calibration showed that the virus titer of the prepared reference was( 4. 96 ± 0. 38) lgCCID50·mL^- 1,with intra-and inter-CVs of 2. 0% -4. 1%. The prepared reference showed high stability. Conclusion: The prepared reference meets the requirements for the national reference for titration of live attenuated mumps vaccine.
出处 《中国新药杂志》 CAS CSCD 北大核心 2014年第20期2450-2452,共3页 Chinese Journal of New Drugs
关键词 腮腺炎减毒活疫苗 国家参考品 协作标定 mumps vaccine national reference collaborative calibration
  • 相关文献

参考文献9

  • 1赵铠,章以浩,李河民.医学生物制品学[M]//陈志慧.流行性腮腺炎疫苗.北京:人民卫生出版社,2007:770-773.
  • 2DAYAN GH,RUBIN S,PLOTKIN S. Mumps outbreaks in vacci- nated populations: are available mumps vaccines effective enough to prevent outbreaks [ J ]. Clin Infect Dis ,2008,47 ( 12 ) : 1458 - 1467.
  • 3DEEKS SL,LIM GH,SIMPSON MA,et al. An assessment of mumps vaccine effectiveness by dose during an outbreak in Cana- da[J]. CMAJ,2011,183(9) : 1014 - 1020.
  • 4张延龄,张辉.疫苗学[M]//王淑珍,刘松友.流行性腮腺炎减毒活疫苗.北京:科学出版社,2004:1239-1241.
  • 5HE HQ,CHEN EF, CHEN HP,et al. Similar immunogenicity of measles-mumps-rubella ( MMR ) vaccine administrated at 8 months versus 12 months age in children[ J]. Vaccine,2014,32 (31) :4001 -4005.
  • 6RUBIN SA, LINK MA, SAUDER CJ, et al, Recent mumps out- breaks in vaccinated populations: no evidence of immune escape [J]. JVirol, 2012, 86(1): 615 -620.
  • 7WHO. Expert committee on Biological standardization[R]. Technical report series,2006.
  • 8THORPE R, WADHWA M. Intended use of Reference products & WHO International Standards/Reference Reagents in the devel- opment of similar biological products (biosimilars) [ J ]. Biologi- cals, 2011,39(5) : 262 -265.
  • 9张洁,李凤祥,徐苗,谭亚军,张华捷,王丽婵,陈玉琴.WHO新版疫苗批签发指导原则介绍[J].中国生物制品学杂志,2012,25(8):1075-1084. 被引量:12

二级参考文献14

  • 1Requirements for dried BCG vaccines//WHO Experts Committee on Biological Standardization. Thirty-six Report [R]. Geneva: World Health Organization, 1987, Annex 2 (WHO Technical Re- port Series, No. 745 ).
  • 2Recommendations for the production and control of poliomyelitis vaccine (oral)//WHO Expert Committee on Biological Standard- ization. Fifty Report JR]. Geneva: World Health Organization, 1999, Annex 1 (WHO Technical Report Series, No. 904).
  • 3Requirements for measles, mumps and rubella vaccines and com- bined vaccines (Live)//WHO Expert Committee on Biological Standardization. Forty-third Report [R]. Geneva: World Health Or- ganization, 1994, Annex 3 (WHO Technical Report Series, No. 840).
  • 4Requirements for Diphtheria, Tetanus, Pertussis and Combined vac- cines//WHO Expert Committee on Biological Standardization. Fortieth Report [R]. Geneva: World Health Organization, 1990, Annex 2 (WHO Technical Report Series, No. 800).
  • 5Guidelines to assure the quality, safety, and efficacy of recombi- nant human papillomavirus virus-like particle vaccine/! WHO Ex- pert Committee on Biological Standardization. Fifty seventh Report [R]. Geneva: World Health Organization, 2006 (WHO Technical Report Series, in press).
  • 6Guidelines to assure the quality, safety and efficacy of live attenu- ated rotavirus vaccines (oral)//WHO Expert Committee on Bio- logical Standardization. Fifty -sixth Report [R]. Geneva: World Health Organization, 2005, Annex 3 (WHO Technical Report Se- ries, No. 941 ).
  • 7Good Manufacturing Practices for pharmaceutical products: main principles//WHO Expert Committee on Biological Standardization IS]. Geneva: World Health Organization 2003. Annex 4 (WHO Technical Report Series, No. 908 ).
  • 8Guidelines for national authorities on quality assurance for biologi- cal products//WHO Expert Committee on Biological Standardiza- tion. Forty-second Report [R]. Geneva: World Health Organization, 1992, Annex 2 (WHO Technical Report Series, No. 822).
  • 9Regulation of vaccines: building on existing drug regulatory author- ities [ S ]. Geneva: World Health Organization, 1999 (WHO / V&B ,99.01 ).
  • 10Yearly biologic product reports for lot release. Health Canada, 2008 [ OL ] .http:// www. hcsc.gc.ca / dhp-mps / brgtherap / ap- plic-demande/guides / lot / index-eng.php.

共引文献11

同被引文献12

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部